Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2007-01-23
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S469000, C548S490000, C548S491000, C546S268100, C546S276400, C546S278100, C514S336000, C514S339000, C514S415000
Reexamination Certificate
active
10714568
ABSTRACT:
The invention relates to substituted 4- or/and 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 4 activity in immunocompetent cells (e.g. macrophages and lymphocytes).
REFERENCES:
patent: 4952587 (1990-08-01), Baker et al.
patent: 5464861 (1995-11-01), Dobrusin et al.
patent: 5556874 (1996-09-01), Dobrusin et al.
patent: 5567711 (1996-10-01), Sheppard et al.
patent: 6008231 (1999-12-01), Lebaut et al.
patent: 6251923 (2001-06-01), Hofgen et al.
patent: 6545025 (2003-04-01), Hofgen et al.
patent: 6545158 (2003-04-01), Hofgen et al.
patent: 6602890 (2003-08-01), Hofgen et al.
patent: 6613794 (2003-09-01), Hofgen et al.
patent: 2002/0111351 (2002-08-01), Hofgen et al.
patent: 2002/0115651 (2002-08-01), Hofgen et al.
patent: 2002/0119971 (2002-08-01), Hofgen et al.
patent: 2002/0137745 (2002-09-01), Hofgen et al.
patent: 2003/0134876 (2003-07-01), Hofgen et al.
patent: 198 18 964 (1999-11-01), None
patent: 100 53 275 (2002-05-01), None
patent: WO 2004/000832 (2003-12-01), None
Baker et al (1990): STN International HCAPLUS database, Columbus (Ohio), accession No. 1990:139035.
Dillard et al (1996): STN International HCAPLUS database, Columbus (Ohio), accession No. 1996:713059.
Barnes, Chronic obstructive pulmonary disease: new opportunities for drug development, TiPS—Oct. 1998 (vol. 19).
Beavo, et al., Multiple Cyclic Nucleotide Phosphodiesterses, Molecular Pharmacology, 46, 1994.
Bertaccini, et al., Synthesis and pharmacological activity of some 5-methoxyidole derivatives occuring in nature, II Farmaco, N. 4, Apr. 1967.
Grossman, The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD, CHEST, 113/4, 1998.
Hall, Isoenzyme selective phosphodiesterase inhibitiors: potential clinical uses, J. Clin. Pharmac., 1993, 35.
Jersmann, et al., Enhancement of lipopolysaccharide-induced neutrophil oxygen radical production by tumor necrosis factor alpha, Infection and Immunity, Apr. 1998.
Karlsson, et al., Phosphodiesterase 4 inhibitors for the treatment of asthma, Ashley Publication Ltd., 1997.
Kummer, Asthma und COPD, Atemw.-Lungenkrkh.Jahrgang 20, No. 5, 1994.
Norman, COPD: new developments and therapeutic opportunities, Drugs News Prospect 11(7), Sep. 1998.
Rennard, COPD: overview of definitions, epidemiology, and factors influencing its development, CHEST, 113/4, Apr. 1998.
Schudt, et al., Phosphodiesterase inhibitors, Academic Press, 1996.
Thorphy, et al., Phosphodiesterase inhibitors: new opportunities for the treatment of asthma, Thorax, 1991.
Thorphy, et al., Novel phosphodiesterase inhibitors for the therapy of asthma, DN&P 6(4), May 1993.
Wenisch, et al., Effect of pentoxifylline in vitro on neutrophil reactive oxygen production and phagocytic ability assessed by flow cytometry, Clin. Drug Invest., Feb. 1997.
Wilson, The role of infection in COPD, CHEST, 1998.
Egerland Ute
Gasparic Antje
Hartenhauer Helge
Höfgen Norbert
Kuss Hildegard
Elbion AG
Shameem Golam M. M.
LandOfFree
Hydroxyindoles, their use as inhibitors of phosphodiesterase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxyindoles, their use as inhibitors of phosphodiesterase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxyindoles, their use as inhibitors of phosphodiesterase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3819591